Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the approval notice for the marketing registration of human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approved drug, human coagulation factor IX, is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug is expected to significantly increase the levels of human coagulation factor IX in the blood, thereby achieving the goal of preventing and treating bleeding [1]

Core Viewpoint - The report emphasizes the commitment of Zhangqiu District to high-quality development through the "Project Empowerment Year," aiming for a GDP growth of approximately 5.3% by 2026 while focusing on four key positioning areas: "Qilu Technology Innovation Manufacturing High Ground," "Longshan Spring Cultural Tourism City," "Jinan School-City Collaborative Integration Demonstration Zone," and "Modernized Strong District in Jinan Metropolitan Area" [2][3][4]. Economic Growth Targets - The main expected economic development targets for 2026 include a GDP growth of around 5.3%, a general public budget revenue increase of 3%, and an industrial added value growth of 7.5% [4]. - The social retail sales of consumer goods are projected to grow by 3.5%, with urban residents' per capita disposable income growth synchronized with economic growth, while rural residents' income growth is expected to exceed that of urban residents [4]. Investment and Consumption Strategies - The report highlights the importance of expanding domestic demand and enhancing economic recovery through initiatives like promoting large consumer goods replacement and expanding urban and rural consumption markets [5]. - Investment structure optimization is emphasized, with a focus on industrial investment, high-tech investment, and new investment, aiming to increase the share of private investment by 4 percentage points [5]. Industrial Development and Upgrading - Zhangqiu District aims to strengthen the real economy by promoting key projects in the main industrial chain, including new energy and intelligent manufacturing [6]. - The district plans to enhance the digital economy and logistics industries, with a target of reaching 210 service enterprises and a revenue of over 11.5 billion yuan in the service sector [6]. Innovation and Talent Development - The report stresses the creation of an innovation and entrepreneurship ecosystem, focusing on the construction of innovation clusters around universities and the establishment of new research platforms [7]. - It aims to cultivate a talent pool by introducing and training over 15 high-level talents and incubating more than 10 quality talent projects [7]. Rural Revitalization Initiatives - Rural revitalization is prioritized, with plans to create high-standard farmland and develop modern facility agriculture, aiming for stable production capacities in various agricultural sectors [8]. - The district also plans to enhance rural living conditions and increase farmers' income through asset utilization reforms and training programs [8]. Urban Development and Public Services - The report outlines urban governance and ecological protection efforts, including infrastructure projects and environmental management to improve living standards [9]. - It emphasizes the importance of social security and public service equalization, with initiatives to enhance education and healthcare services [10].

格隆汇2月4日丨复宏汉霖(02696.HK)发布公告，合计约1.83亿股非上市股已于2026年2月4日完成转换为 H股，该等转换H股将于2026年2月5日上午九时正开始于联交所上市。 ...

智通财经APP讯，复宏汉霖(02696)发布公告，合计1.83亿股非上市股已于2026年2月4日完成转换为H 股，该等转换H股将于2026年2月5日上午九时正开始于联交所上市。 ...

复宏汉霖(02696)发布公告，合计1.83亿股非上市股已于2026年2月4日完成转换为H股，该等转换H股将 于2026年2月5日上午九时正开始于联交所上市。 ...

Core Viewpoint - The company, Palin Bio (000403.SZ), announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approval signifies a significant milestone for the company in the biopharmaceutical sector [1] - The drug is expected to enhance the company's product portfolio and market presence in the coagulation factor segment [1] - This development may lead to potential revenue growth and increased investor interest in the company [1]

Core Viewpoint - The company, Palin Bio (000403.SZ), announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approval signifies a significant milestone for the company in the biopharmaceutical sector [1] - The drug is expected to enhance the company's product portfolio and market presence in the coagulation therapy segment [1]

Core Viewpoint - Palin Bio (000403.SZ) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The human coagulation factor IX is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug significantly enhances the levels of human coagulation factor IX in the blood, thereby preventing and treating bleeding [1] - Hemophilia B is classified as a rare disease, and there is a long-term shortage of clinical medications, with existing treatments having room for improvement in active recovery rates [1] Group 2 - The company is committed to patient-centered approaches and aims to develop blood-derived drugs with high recovery rates [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the drug registration approval notice from the National Medical Products Administration for human coagulation factor IX, which is intended for treating patients with hemophilia B due to congenital factor IX deficiency or other causes of low factor IX levels [1] Group 1 - The drug is indicated for patients with congenital hemophilia B or those with low levels of human coagulation factor IX due to other reasons [1] - The treatment aims to significantly increase the levels of human coagulation factor IX in the blood, thereby preventing and treating bleeding episodes [1]

Core Viewpoint - The Sci-Tech Innovation 50 Index experienced a decline, closing at 1453.48 points with a drop of 1.20% on February 4, 2023, amidst a total trading volume of approximately 765.9 billion yuan [1]. Group 1: Market Performance - The majority of stocks on the Sci-Tech Board saw declines, with 209 stocks rising. High-priced stocks showed mixed performance while low-priced stocks mostly increased [2]. - On average, the 600 stocks on the Sci-Tech Board experienced a decline of 0.64%, with an average turnover rate of 2.89% and a total trading volume of 242.9 billion yuan, alongside an average fluctuation of 4.16% [2]. Group 2: Individual Stock Performance - Shichuang Energy and JinkoSolar led the gainers with a rise of 20%, while Kaipu Cloud had the largest drop at 12.57% [3]. - In terms of trading volume, Cambrian Technology topped the list with a trading volume of 12.6 billion yuan, while Hanbang Technology had the lowest at 1.302 million yuan [4]. Group 3: Turnover Rate - Hengyun Chang had the highest turnover rate at 26.8%, while Bairen Medical recorded the lowest turnover rate at 0.17% [5].